Valeant Pharmaceuticals (VRX) has agreed to acquire Obagi Medical Products (OMPI) for $360M,...


Valeant Pharmaceuticals (VRX) has agreed to acquire Obagi Medical Products (OMPI) for $360M, with the $19.75/share offer representing a 42% premium to Obagi's closing price on Thursday last week, a day before it released its 2012 earnings results. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs